RDY - Appili Therapeutics advances late-stage study of favipiravir for COVID-19

Dosing is underway in a Phase 3 clinical trial, PRESECO, evaluating Appili Therapeutics' (APLIF) Avigen tablets (favipiravir) for the treatment of COVID-19 patients with mild-to-moderate symptoms. The goal is to alleviate the symptoms and prevent disease progression.Enrollment target is ~826 subjects. The primary endpoint is time to sustained recovery from day 0 to day 21 compared to placebo.Preliminary data should be available in H1 2021.Favipiravir is a broad-spectrum antiviral developed by FUJIFILM Toyama Chemical Co., Ltd. (FUJIF). It is approved in Japan for the treatment of influenza. Based on encouraging clinical data, Russia and India recently approved its emergency use for COVID-19. FUJIFILM recently announced positive results from a Phase 3 study in hospitalized COVID-19 patients.Appili is part of a consortium that includes Dr. Reddy's Laboratories (RDY), Global Response Aid and FUJIFILM backing global development and distribution (ex. Japan, China and Russia) of Avigan tablets for the potential treatment and

For further details see:

Appili Therapeutics advances late-stage study of favipiravir for COVID-19